Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy

Journal of Virology

Volumn 70, Issue 2, 1996, Pages 1086-1090

  Iversen, Astrid K N ^a,b,d   Shafer, Robert W ^a   Wehrly, Kathy ^c   Winters, Mark A ^a   Mullins, James I ^b,e   Chesebro, Bruce ^c   Merigan, Thomas C ^a  

^a Center for AIDS Research   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SITE DIRECTED MUTAGENESIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0030048748     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.2.1086-1090.1996     Document Type: Article

References (29)

1. Back, N. K. T., M. Nijhuis, C. A. B. Boucher, D. de Jong, R. Schuurman, B. O. Essink, and B. Berkhout. 1994. Reduced in vitro polymerase activity of 3TC-resistant reverse transcriptase enzymes, p. 32. Programme and Abstracts of the 3rd International Workshop on HIV Drug Resistance, 1994.
2. Boyer, P. L., C. Tantillo, A. Jacob-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994 Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length: the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci USA 91:4882-4886.
3. Chesebro, B., and K. Wehrly. 1988. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62:3779-3788.
4. Chesebro, B., K. Wehrly, J. Metcalf, and D. E. Griffin. 1991. Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients. J Infect. Dis. 163:64-70.
5. Coffin, J. M. 1995 HIV population dynamics in vivo, implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
6. Doolittle, R. F., D. F. Feng, M. S. Johnson, and M. A. McClure. 1989 Origins and evolutionary relationships of retroviruses Quart. Rev. Biol. 64:1-30.
7. Emini, E. A., D. J. Graham, L. Gotleib, J. Condra, V. W. Byrnes, and W. A. Schleif. 1993. HIV and multidrug resistance. Nature (London) 364:679.
8. Jacob-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, X. Lu, C. Tantillo, R. L. Williams, G. Kramer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase completed with double-stranded DNA at 3.0 Ä resolution shows bent DNA. Proc Natl. Acad. Sci. USA 90:6320-6324
9. Kleim, J. P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, and G. Rieb. 1994. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology 200:696-701.
10. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3 5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
11. Lacey, S. F., and B. A. Larder. 1994. Novel mutation (V75T) in human immunodeficiency virus type 1 confers resistance to 2′,3′-didehydro-2′,3′- dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 38:1428-1432.
12. Larder, B. A. 1992. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669
13. Larder, B. A., and C. A. B. Boucher. 1993. PCR detection of human immunodeficiency virus drug resistance mutations, p. 527-533. In D. H. Persing, T. F. Smith, F. C. Tenover, and T. J. White (ed.), Diagnostic molecular microbiology. American Society for Microbiology. Washington, D C
14. Larder, B. A., B. Chesebro, and D. D. Richman. 1990. Susceptibilities of zidovudine-sensitive and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay Antimicrob. Agents Chemother. 34:436-441.
15. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy Science 243:1731-1734.
16. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature (London) 365:451-453.
17. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
18. McClary, J. A., F. Witney, and J. Geisselsoder. 1989. Efficient site-directed in vitro mutagenesis using phagemid vectors. Biotechniques 7:282-289.
19. Mitsuya, H., and S. Broder. 1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides Proc. Natl. Acad. Sci. USA 83:1911-1915.
20. Poch, O., I. Sauvaget, M. Delarue, and N. Tordo. 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8:3867-3874.
21. Richman, D. D. 1992. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother 37: 1207-1213.
22. Shafer, R. W., A. K. N. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, T. C. Merigan, and ACTG 143 Virology Team. 1995. Drug resistance and heterogeneous long-term virological responses of human immunodeficiency virus type 1 (HIV)-infected individuals to zidovudine and didanosine combination therapy. J Infect. Dis. 172:70-78.
23. Shafer, R. W., M. J. Kozal, D. A. Katzenstein, W. H. Lipil, I. F. Johnstone, and T. C. Merigan. 1993. Zidovudine susceptibility testing of human immunodeficiency virus type 1 clinical isolates J. Virol. Methods 41:297-310
24. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. N. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729
25. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995 Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
26. Shirasaka, T., R. Yarchoan, M. O'Brien, R. Husson, B. Anderson, E. Kojima, S. Broder, and H. Mitsuya. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study Proc. Natl. Acad Sci. USA 90:562-566
27. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
28. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase Proc. Natl. Acad Sci. USA 90:5653-5656.
29. Winters, M. A., L. B. Tan, D. A. Katzenstein, and T. C. Merigan. 1993. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J. Clin. Microbiol 31:2960-2966.